Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
NCT ID: NCT01780506
Last Updated: 2018-11-19
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
872 participants
INTERVENTIONAL
2012-12-26
2017-09-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
NCT01497899
Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
NCT01797445
Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
NCT01095796
Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
NCT01106586
Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
NCT02607956
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
E/C/F/TAF (Double-Blind Phase)
E/C/F/TAF plus E/C/F/TDF placebo for 144 weeks
E/C/F/TAF
150/150/200/10 mg FDC tablet administered orally once daily
E/C/F/TDF Placebo
Tablet administered orally once daily
E/C/F/TDF (Double-Blind Phase)
E/C/F/TDF plus E/C/F/TAF placebo for 144 weeks
E/C/F/TDF
150/150/200/300 mg FDC tablet administered orally once daily
E/C/F/TAF Placebo
Tablet administered orally once daily
Open-Label Extension Phase
After study unblinding, participants who complete 144 weeks of the study had the option to receive open-label E/C/F/TAF until commercially available, or until Gilead Sciences terminated the study in that country.
E/C/F/TAF
150/150/200/10 mg FDC tablet administered orally once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
E/C/F/TAF
150/150/200/10 mg FDC tablet administered orally once daily
E/C/F/TDF
150/150/200/300 mg FDC tablet administered orally once daily
E/C/F/TDF Placebo
Tablet administered orally once daily
E/C/F/TAF Placebo
Tablet administered orally once daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Plasma HIV-1 RNA levels ≥ 1,000 copies/mL at screening
* No prior use of any approved or investigational antiretroviral drug for any length of time, except the use for pre-exposure prophylaxis (PREP) or post-exposure prophylaxis (PEP), up to 6 months prior to screening
* Screening genotype report must show sensitivity to elvitegravir, emtricitabine, tenofovir disoproxil fumarate (tenofovir DF)
* Normal electrocardiogram (ECG)
* Estimated glomerular filtration rate (eGFR) ≥ 50 mL/min according to the Cockcroft-Gault formula for creatinine clearance
* Hepatic transaminases (AST and ALT) ≤ 5 × upper limit of normal (ULN)
* Total bilirubin ≤ 1.5 mg/dL, or normal direct bilirubin
* Adequate hematologic function
* Serum amylase ≤ 5 × ULN
* Males and females of childbearing potential must agree to utilize highly effective contraception methods or be non-heterosexually active or practice sexual abstinence from screening throughout the duration of study treatment and for 30 days following the last dose of study drug
* Females who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least three months prior to study dosing
* Females who have stopped menstruating for ≥ 12 months but do not have documentation of ovarian hormonal failure must have a serum follicle stimulating hormone (FSH) level at screening within the post-menopausal range based on the Central Laboratory reference range
Exclusion Criteria
* Hepatitis B surface antigen (HBsAg) positive
* Hepatitis C antibody positive
* Individuals experiencing decompensated cirrhosis
* Females who are breastfeeding
* Positive serum pregnancy test
* Have an implanted defibrillator or pacemaker
* Current alcohol or substance use judged by the Investigator to potentially interfere with study compliance
* History of malignancy within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, noninvasive cutaneous squamous carcinoma
* Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to baseline
* Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the individual unsuitable for the study or unable to comply with dosing requirements
* Participation in any other clinical trial (including observational trials) without prior approval
* Individuals receiving ongoing therapy with drugs not to be used with elvitegravir, cobicistat, emtricitabine, tenofovir DF, and TAF or individuals with any known allergies to the excipients of E/C/F/TDF or E/C/F/TAF single-tablet regimen tablets
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gilead Sciences
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gilead Study Director
Role: STUDY_DIRECTOR
Gilead Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The University of Alabama at Birmingham
Birmingham, Alabama, United States
Spectrum Medical Group
Phoenix, Arizona, United States
Kaiser Permanente Los Angeles
Los Angeles, California, United States
University of California, Los Angeles
Los Angeles, California, United States
Peter J. Ruane, MD, Inc.
Los Angeles, California, United States
Anthony Mills MD Inc
Los Angeles, California, United States
East Bay AIDS Center
Oakland, California, United States
Kaiser Permanente - Sacramento
Sacramento, California, United States
La Playa Medical Group and Clinical Research
San Diego, California, United States
University of California, San Diego
San Diego, California, United States
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Torrance, California, United States
Apex Research, LLC
Denver, Colorado, United States
Yale University School of Medicine
New Haven, Connecticut, United States
Dupont Circle Physicians Group, P.C.
Washington D.C., District of Columbia, United States
Whitman Walker Clinic
Washington D.C., District of Columbia, United States
Capital Medical Associates, P.C.
Washington D.C., District of Columbia, United States
Gary Richmond, MD, PA, Inc.
Fort Lauderdale, Florida, United States
Midway Immunology & Research Center, LLC
Ft. Pierce, Florida, United States
The Kinder Medical Group
Miami, Florida, United States
AIDS Healthcare Foundation
Miami Beach, Florida, United States
Orlando Immunology Center
Orlando, Florida, United States
IDOCF/ValuHealthMD, LLC
Orlando, Florida, United States
Infectious Diseases Associates
Pensacola, Florida, United States
The University of South Florida
Tampa, Florida, United States
Infectious Disease Research Institute Inc.
Tampa, Florida, United States
St. Joseph's Comprenhensive Research Inisitute
Tampa, Florida, United States
AIDS Research and Treatment Center of the Treasure Coast
Vero Beach, Florida, United States
AIDS Research Consortium of Atlanta
Atlanta, Georgia, United States
Emory University
Atlanta, Georgia, United States
Atlanta ID Group, PC
Atlanta, Georgia, United States
Infectious Disease Specialist of Atlanta
Decatur, Georgia, United States
Mercer University School of Medicine
Macon, Georgia, United States
University of Hawaii - Hawaii Center for AIDS
Honolulu, Hawaii, United States
Northwestern University
Chicago, Illinois, United States
Ruth M. Rothstein CORE Center
Chicago, Illinois, United States
Howard Brown Health Center
Chicago, Illinois, United States
Institute of Human Virology, University of Maryland
Baltimore, Maryland, United States
Community Research Initative
Boston, Massachusetts, United States
Brigham & Women's Hospital
Boston, Massachusetts, United States
Metrowest Medical Center
Framingham, Massachusetts, United States
Baystate Infectious Diseases Clinical Research
Springfield, Massachusetts, United States
Be Well Medical Center
Berkley, Michigan, United States
Henry Ford Hospital
Detroit, Michigan, United States
Hennepin County Medical Center
Minneapolis, Minnesota, United States
Central West Clinical Research, Inc.
St Louis, Missouri, United States
Southampton Healthcare, Inc.
St Louis, Missouri, United States
ID Care
Hillsborough, New Jersey, United States
Saint Michael's Medical Center
Newark, New Jersey, United States
Southwest C.A.R.E. Center
Santa Fe, New Mexico, United States
Albany Medical College
Albany, New York, United States
Upstate Infectious Diseases Associates
Albany, New York, United States
New York Hospital Queens
Flushing, New York, United States
North Shore University Hospital - Division of Infectious Diseases
Manhasset, New York, United States
Mount Sinai School of Medicine
New York, New York, United States
Jacobi Medical Center
The Bronx, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
University of North Carolina
Chapel Hill, North Carolina, United States
Infectious Disease Consultants, PA
Charlotte, North Carolina, United States
Duke University
Durham, North Carolina, United States
Rosedale Infectious Diseases
Huntersville, North Carolina, United States
Summa Health Care Center
Akron, Ohio, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
The Miriam Hospital
Providence, Rhode Island, United States
Medical University of South Carolina
Charleston, South Carolina, United States
University of South Carolina School of Medicine
Columbia, South Carolina, United States
Central Texas Clinical Research
Austin, Texas, United States
St. Hope Foundation, Inc.
Bellaire, Texas, United States
Trinity Health and Wellness Center/AIDS Arms, Inc.
Dallas, Texas, United States
North Texas Infectious Diseases Consultants
Dallas, Texas, United States
Tarrant County Infectious Disease Associates
Fort Worth, Texas, United States
Garcias' Family Health Group
Harlingen, Texas, United States
Therapeutic Concepts, PA
Houston, Texas, United States
Gordon E. Crofoot, MD, PA
Houston, Texas, United States
DCOL Center for Clinical Research
Longview, Texas, United States
Clinical Alliance for Research & Education - Infectious Diseases, LLC (CARE-ID)
Annandale, Virginia, United States
Peter Shalit, MD
Seattle, Washington, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Holdsworth House Medical Practice
Darlinghurst, New South Wales, Australia
Taylor Square Private Clinic
Darlington, New South Wales, Australia
East Sydney Doctors
Sydney, New South Wales, Australia
Albion Street Centre
Sydney, Southwest, Australia
Melbourne Sexual Health Clinic
Carlton, Victoria, Australia
DIAID, Department of Dermatology, Medical University Vienna
Vienna, , Austria
Otto-Wagner-Spital, Sozialmedizinisches Zentrum Baumgartner Hoehe
Vienna, , Austria
Hôpital Erasme-ULB
Anderlecht, Brussels Capital, Belgium
CHU Saint-Pierre University Hospital
Brussels, , Belgium
Spectrum Health
Vancouver, British Columbia, Canada
Health Sciences Centre Winnipeg
Winnipeg, Manitoba, Canada
The Ottawa Hospital
Ottawa, Ontario, Canada
Maple Leaf Research
Toronto, Ontario, Canada
Clinique Medicale Du Quartier Latin
Montreal, Quebec, Canada
Clinique medicale l'Actuel
Montreal, Quebec, Canada
Clinique OPUS
Montreal, Quebec, Canada
Sunnybrook Health Science Center
Toronto, , Canada
Ospedale San Raffaele
Milan, , Italy
National Center for Global Health and Medicine AIDS Clinical Center
Shinjuku-ku, Tokyo, , Japan
HOPE Clinical Research
San Juan, , Puerto Rico
Hospital Germans Trias i Pujol
Badalona, , Spain
Hospital del Mar
Barcelona, , Spain
Hospital Universitari Vall D'Hebron
Barcelona, , Spain
Hospital Clinic i Provincial
Barcelona, , Spain
University Hospital Bellvitge
Barcelona, , Spain
Hospital General Universitario Gregorio Maranon
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Hospital Universitario La Paz
Madrid, , Spain
Complejo Hospitalario Universitario de Santiago (CHUS)
Santiago de Compostela, , Spain
Universitätsspital Bern
Bern, , Switzerland
Centre Hospitalier Universitaire Vaudois
Lausanne, , Switzerland
University Hospital, Zurich
Zurich, , Switzerland
The HIV Netherland Australia Thailand, Thai Red Cross AIDS Research Center (The HIV-NAT)
Bangkok, , Thailand
Ramathibodi Hospital, Mahidol University
Bangkok, , Thailand
Siriraj Hospital
Bangkok, , Thailand
Chiang Mai University
Chiang Mai, , Thailand
Khon Kaen University
Khon Kaen, , Thailand
Bamrasnaradura Infectious Diseases Institute
Nonthaburi, , Thailand
Chelsea & Westminster Hospital
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczer D, Molina JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custodio JM, Plummer A, Zhong L, Cao H, Martin H, Callebaut C, Cheng AK, Fordyce MW, McCallister S; GS-US-292-0104/0111 Study Team. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015 Jun 27;385(9987):2606-15. doi: 10.1016/S0140-6736(15)60616-X. Epub 2015 Apr 15.
Arribas JR, Thompson M, Sax PE, Haas B, McDonald C, Wohl DA, DeJesus E, Clarke AE, Guo S, Wang H, Callebaut C, Plummer A, Cheng A, Das M, McCallister S. Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results. J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):211-218. doi: 10.1097/QAI.0000000000001350.
Margot N, Cox S, Das M, McCallister S, Miller MD, Callebaut C. Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate. Antivir Ther. 2017;22(5):443-446. doi: 10.3851/IMP3125. Epub 2017 Jan 11.
Margot NA, Kitrinos KM, Fordyce M, McCallister S, Miller MD, Callebaut C. Rare emergence of drug resistance in HIV-1 treatment-naive patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. HIV Clin Trials. 2016 Mar;17(2):78-87. doi: 10.1080/15284336.2016.1142731.
Funderburg NT, McComsey GA, Kulkarni M, Bannerman T, Mantini J, Thornton B, Liu HC, Zhang Y, Song Q, Fang L, Dinoso J, Cheng A, McCallister S, Fordyce MW, Das M. Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide. EBioMedicine. 2016 Nov;13:321-327. doi: 10.1016/j.ebiom.2016.10.009. Epub 2016 Oct 11.
Wohl D, Oka S, Clumeck N, Clarke A, Brinson C, Stephens J, Tashima K, Arribas JR, Rashbaum B, Cheret A, Brunetta J, Mussini C, Tebas P, Sax PE, Cheng A, Zhong L, Callebaut C, Das M, Fordyce M; GS-US-2,92-01040111 and Study Team. Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results. J Acquir Immune Defic Syndr. 2016 May 1;72(1):58-64. doi: 10.1097/QAI.0000000000000940.
Custodio JM, Garner W, Callebaut C, Fordyce M, Plummer A, Zhong L, et al. The Pharmacokinetics of Tenofovir and Tenofovir Diphosphate Following Administration of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate [Oral Abstract #6]. The 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy. Washington DC, USA, May 26-28, 2015.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-004458-27
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
GS-US-292-0104
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.